ContraFect Corporation (CFRXQ)
OTCMKTS · Delayed Price · Currency is USD
0.0005
0.00 (0.00%)
At close: Jul 22, 2025

ContraFect Company Description

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States.

Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus.

The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections.

It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections.

In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients.

Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis.

The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens.

ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York. On December 4, 2023, ContraFect Corporation filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

ContraFect Corporation
CountryUnited States
Founded2008
IndustryBiotechnology
SectorHealthcare
Employees23

Contact Details

Address:
28 Wells Avenue
Yonkers, Delaware 10701
United States
Phone914 207 2300
Websitecontrafect.com

Stock Details

Ticker SymbolCFRXQ
ExchangeOTCMKTS
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
ISIN NumberUS2123264093
SIC Code2836

Key Executives

NamePosition
Michael Messinger CPAChief Executive Officer, President, Chief Financial Officer and Principal Accounting Officer
Natalie Bogdanos J.D.General Counsel, Corporate Secretary and Data Protection Officer
Matthew Salamone P.H.R., SPHRVice President of Human Resources
Dr. Gary WoodnuttSenior Vice President of Translational Sciences and Preclinical Development
Dr. William Garrett Nichols M.D., M.S.Interim Chief Medical Officer